Institute of Preventive Medicine, NDMC, TAIWAN.
Report No: IPM/202103-01
Testing Period: 2021-01-27-02-22
The following test samples are provided and confirmed by the supplier:
Request partner and developer: PUU LIH Bio-Technology Co., Ltd.(普力生化科技股份有限公司)
Product name: PL600 Chlorine Dioxide antibacterial tablet(普力-600)
Testing purpose: To evaluate whether the PL600 Chlorine Dioxide antibacterial tablet (PL600) has the function of inhibiting SARS-CoV-2 virus(新冠病毒),also ensure its declared efficacy and quality.
also ensure its declared efficacy and quality.
Firstly, PL600 and SARS-CoV-2 virus were put together for 30 minutes according to the standard testing time in the laboratory. Then, the liquid was added to the cells to observe the generation of virus plaque.
The PL600 and SARS-CoV-2 virus were put together for 1 hour in 37 C, according to the standard testing time in the laboratory. After 72 hours of reaction, the liquid was added to the cells to observe the virus plaque formation. The higher value of viral inhibition rate (%), better is the ability to suppress viruses.
The results show that the PL600 can inhibit the formation of virus plaque with the efficiency of more than 99.99%. The control group was added with the ddH20 buffer, and the control group had a virus suppression effect of 0%. Based on the above experimental results on the inhibition of SARS-CoV-2 virus was inhibited by the PL600 efficiently.
1. This report is for the tests carried out on the samples provided by the request partner.
2. The data modification of this test report is invalid.
3. Application of this test report is invalid without agreement from Institute of Preventive Medicine, NDMC, TAIWAN.
4. Memorandum of Understanding approved document No: 國醫衛勤字第1100020256 號.